Therefore, we analyzed the genetic profiles of 131 patients with stage I to stage IIIA EGFR-mutated lung adenocarcinoma using NGS and compared the risk of recurrence based on co-occurring actionable mutations, the number of co-mutations, EGFR mutation types, and 19-del subtypes. Here, EGFR is linked to lung adenocarcinoma.